Please assess the completion status of the following clinical trial:

Trial Title: Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease~* Documented evidence of disease progression following most recent therapy~* Estimated life expectancy greater than 12 weeks~Exclusion Criteria:~* Pregnant or breastfeeding~* Prior chemotherapy or brain radiotherapy within 4 weeks of entering study~* Receiving other investigational agents~* Untreated or progressive brain metastases~* Prior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib~* Known HIV positive on combination antiretroviral therapy~* Clinically uncontrolled hypertension~* Previous or concurrent malignancy except adequately treated basal or squamous cell skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 5 years~* Active or uncontrolled clinically significant infection~* Chronic GI disease that may affect bioavailability of ponatinib~* History of significant bleeding disorder unrelated to cancer~* Uncontrolled intercurrent illness~* Clinically significant ventricular arrythmia~* History of chronic pancreatitis, alcohol abuse or uncontrolled hypertriglyceridemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ponatinib Treatment Arm (Type: EXPERIMENTAL): Ponatinib taken by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).